dryadpublic
Data from: Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
ShareScore
24/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 0
- Harmonization
- 8
- Access
- 12
- Reuse readiness
- 0
- Engagement
- 4
Dataset details
- Repository
- dryad
- Published
- May 29, 2019
- License
- Not reported
- DOI
- doi:10.5061/dryad.vg6jp14
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.